drugset / Trial / NCT04209556
A Study To Evaluate The Safety And Efficacy Of PF-06826647 In Participants With Moderate To Severe Ulcerative Colitis
RandomizedParallel-groupQuadruple-blindTreatment
Summary
The purpose of this study is to evaluate efficacy and safety of PF-06826647 in moderate to severe ulcerative colitis
Timeline
- Start
- 2020-09-30
- Primary completion
- 2023-10-26
- Completion
- 2023-10-26
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | ROPSACITINIB | Small molecule | 100 mg | — |
| Subject | ROPSACITINIB | Small molecule | 300 mg | — |
| Subject | ROPSACITINIB | Small molecule | 400 mg | — |
| Subject | ROPSACITINIB | Small molecule | 600 mg | — |